Tamsulosin is a highly selective α1-adrenoreceptor antagonist. It has been developed to treat signs and symptoms of benign prostatic hyperplasia. Tamsulosin is absorbed quickly and completely in intestinal mucosa and is eliminated gradually after oral administration, which might generate some side effects as postural hypotension in number of patients. Transdermal drug delivery systems were developed for prolonged tamsulosin delivery in order to control its bioavailability and minimize its side effects. Hence, the present review aims to discuss thoroughly the various transdermal drug delivery systems of tamsulosin investigated in recent years. This review also discusses the skin as a route of drug administration, technologies in transdermal drug delivery along with different techniques used in the preparation of transdermal delivery systems of tamsulosin and their effects on its release and permeation.

Hydrogels are hydrophilic three-dimensional polymeric networks which has the capability to absorb water or biological fluids. These polymeric network is formulated through chemical crosslinking or physical crosslinking mechanisms. Several polymers of synthetic and natural origin can be used to form hydrogels. Mechanical properties, swelling and biological properties are about the most significant hydrogels properties that can affect their morphology and structure. Hydrogels are promising biomaterials due to their significant properties as hydrophilicity, biodegradability, biocompatibility and non-toxicity. These characteristics make hydrogels appropriate for medical and pharmaceutical application. This review discusses the types of hydrogels, their properties, mechanism of preparation and applications of hydrogels as drug delivery system.

Background/Objectives: Breast cancer remains the most prevalent malignancy among women worldwide, with letrozole (LZ) serving as a critical aromatase inhibitor for hormone receptor–positive cases. However, long-term oral administration of LZ is often associated with systemic adverse effects and poor patient compliance. To overcome these limitations, new non-aqueous nanoemulgels (NEMGs) were developed for transdermal delivery of LZ. Methods: The NEMGs were formulated using glyceryl monooleate (GMO), Sepineo P600^®, Transcutol, propylene glycol, and penetration enhancers propylene glycol laurate (PGL), propylene glycol monocaprylate (PGMC), and Captex^®. Physicochemical characterization, solubility, stability, and in vitro permeation studies were conducted using Strat-M^® membranes, while in vivo pharmacokinetics were evaluated in rat models. Results: The optimized GMO/PGMC-based NEMG demonstrated significantly enhanced drug flux, higher permeability coefficients, and shorter lag times compared with other NEMGs and suspension emulgels. In vivo, transdermal application of the GMO/PGMC-based NEMG over an area of 2.55 cm² produced dual plasma absorption peaks, with 57% of the LZ dose absorbed relative to oral administration over 12 days. Shelf-life and accelerated stability assessments confirmed excellent physicochemical stability with negligible crystallization. Conclusions: The developed LZ NEMG formulations offer a stable, effective, and patient-friendly transdermal drug delivery platform for breast cancer therapy. This system demonstrates potential to improve patient compliance and reduce systemic toxicity compared to conventional oral administration.